trial · primary record
Tocilizumab
Ischemic Stroke
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 348 |
| Primary completion | 2027-04-20 |
| Primary endpoint | Proportion of patients with a modified Rankin Scale (mRS) score of 0-3 at 90 days. |
| Registry ID | NCT07509645 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:46.417Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07509645
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Tocilizumab · approval
- Tocilizumab · compound